NEW YORK (GenomeWeb) – The US Food and Drug Administration has expanded the labeling for Roche's Cobas EGFR Mutation Test v2 as a companion diagnostic that can analyze plasma samples from non-small cell lung cancer patients considering treatment with AstraZeneca's Tagrisso (osimertinib). 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.